Aubert I, Emmerich J, Charpak Y, Chanu B, Dachet C, Herlich D, Besseau M, Rouffy J, Jacotot B
Service de Médecine interne et Pathologie vasculaire, Hôpital Saint-Louis, Paris.
Presse Med. 1988 May 14;17(18):901-4.
We studied the effects of simvastatin (MK 733), a new competitive inhibitor of HMG CoA reductase, alone and in combination with a bile acid sequestrant, cholestyramine, on serum levels of lipoproteins and apoproteins A1 and B, in 24 patients with familial hypercholesterolemia. After simvastatin treatment (40 mg/day) alone for 12 weeks, serum total and low density lipoprotein cholesterol decreased by 31 and 36 percent respectively. With the addition of cholestyramine, there was a 41 per cent total decrease in serum cholesterol from the control value and a 50 percent decrease in low density lipoprotein cholesterol. After cholestyramine treatment alone for 12 weeks, serum total and low density lipoprotein cholesterol decreased by 20 percent and 29 percent respectively. With the addition of simvastatin (20 mg per day), there was a 32 percent total decrease in serum cholesterol from the control value and a 43 percent decrease in low density lipoprotein cholesterol. High density lipoprotein cholesterol remained unchanged. No major adverse effect was observed. If long term safety can be confirmed, the simvastatin-cholestyramine regimen may prove useful in heterozygous familial hypercholesterolemia.
我们研究了新型HMG CoA还原酶竞争性抑制剂辛伐他汀（MK 733）单独使用以及与胆汁酸螯合剂考来烯胺联合使用，对24例家族性高胆固醇血症患者血清脂蛋白及载脂蛋白A1和B水平的影响。单独使用辛伐他汀治疗（40毫克/天）12周后，血清总胆固醇和低密度脂蛋白胆固醇分别下降了31%和36%。加用考来烯胺后，血清胆固醇较对照值总体下降了41%，低密度脂蛋白胆固醇下降了50%。单独使用考来烯胺治疗12周后，血清总胆固醇和低密度脂蛋白胆固醇分别下降了20%和29%。加用辛伐他汀（20毫克/天）后，血清胆固醇较对照值总体下降了32%，低密度脂蛋白胆固醇下降了43%。高密度脂蛋白胆固醇保持不变。未观察到重大不良反应。如果能证实其长期安全性，辛伐他汀-考来烯胺疗法可能对杂合子家族性高胆固醇血症有用。
